Clinical & Translational

The firm said the drop in revenues was due to a lack of milestone payments from Quest Diagnostics, which accounted for half of all revenues in the prior-year period.

Birmingham Women's NHS Foundation Trust said it is partnering with Illumina to develop an NIPT, which it hopes to start offering in September.

As part of the settlement reached with the agency, NMT will also cease all operations, end its plans to reorganize, and liquidate its assets. 

The effort will use Biognosys' HRM method and is part of a move at Biodesix to add a "hypothesis-based approach" to its biomarker work, a company official said.

The firm raised $8 million since May and is no longer obligated to raise an additional $2 million by January 2016, per the original terms of the loan facility.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.